Hypertension in women is often undiagnosed or inadequately treated, especially after menopause when cardiovascular risk increases. In premenopausal women, endogenous estrogens maintain vasodilation and thus contribute to blood pressure control. Aging and the loss of endogenous estrogen production after menopause are accompanied by increases in blood pressure, contributing to the high prevalence of hypertension in older women. Currently, ≈75% of postmenopausal women in the United States are hypertensive. The high prevalence of obesity, the lack of regular physical exercise, and dietary salt are important factors contributing to and aggravating postmenopausal hypertension. In view of the ongoing population aging throughout the world, diagnosis and treatment of hypertension in postmenopausal women are important to reduce the excess burden of associated cardiovascular disease and to improve outcomes of potentially fatal complications such as stroke and myocardial infarction. This article discusses current knowledge about the mechanisms and therapeutic issues related to postmenopausal hypertension.

Hypertension: Important Determinant of Cardiovascular Risk in Women

More than 25% of the female adult world population is hypertensive.\(^1\) Elevations in blood pressure in women are related to cardiovascular risk (Figure, panel A),\(^7,8\) with the prevalence of hypertension being particularly high among women aged ≥60 years.\(^1\) In the United States, ≈75% of postmenopausal women are hypertensive.\(^4\) Hypertension is often accompanied by other cardiovascular risk factors, eg, obesity, dyslipidemia, and diabetes mellitus.\(^5\) It is noteworthy that the prevalence of hypertension-related cardiovascular complications is greater in postmenopausal women than in age-matched men.\(^6\) Indeed, these complications represent the leading cause of death in women.\(^6\)

Clinical studies have documented beneficial effects of antihypertensive therapy on cardiovascular outcome,\(^9\) even in patients ≥80 years of age.\(^7\) Overall recognition, control, and treatment of hypertension in postmenopausal women are still poor in primary care, and hypertension is often not being treated aggressively enough.\(^4,8–10\) Thus, further improvements of medical and public health measures, awareness of patients and physicians, and improved information policies are needed.

Blood Pressure and Endogenous Estrogens: Role of Menopause

Prior to menopause, blood pressure is lower in women compared with age-matched men.\(^11,12\) During the menstrual cycle, blood pressure levels are inversely related to circulating estrogen concentrations and lower when 17β-estradiol levels peak,\(^12\) reflecting the vasodilator activity of endogenous 17β-estradiol.\(^13\) Similarly, increases of endogenous estrogen production during pregnancy contribute to maintenance of normotension despite marked increases in plasma volume and cardiac output.\(^12,14\) The first decade after menopause is accompanied by an increase in blood pressure (Figure, panel B).\(^11,15\) In the seventh decade of life, the prevalence of hypertension among women is even higher than in men, regardless of ethnic background.\(^11,15\) Specifically, there are pronounced increases in both systolic blood pressure and pulse pressure in postmenopausal women, whereas diastolic blood pressure remains at a similar level compared with age-matched men (Figure, panel B).\(^11\) Importantly, elevated systolic blood pressure is considered a more sensitive predictor of future cardiovascular events than diastolic blood pressure.\(^5\)

The role of endogenous estrogens in the pathogenesis of hypertension is complex. Indeed, the effects of hormonal changes after menopause are often masked by the presence of other cardiovascular risk factors, eg, vascular aging, arterial stiffening, obesity, age-dependent changes in insulin sensitivity, and dyslipidemia.\(^16,17\) Cross-sectional studies indicate that menopause increases the risk of hypertension by ≈2-fold, even after adjusting for factors such as age and body mass index.\(^18,19\) Both early onset of menopause and a long postmenopausal period are associated with higher blood pressure levels.\(^20\) Moreover, hypoestrogenemic premenopausal women diagnosed with the polycystic ovary syndrome and menstrual irregularities because of ovarian failure are at a higher risk of developing hypertension, coronary artery disease, and adverse cardiovascular events and experience

Received July 20, 2008; first decision August 13, 2008; revision accepted April 16, 2009.
From the Departement für Innere Medizin, Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich, Zürich, Switzerland.
Correspondence to Matthias Barton, Departement für Innere Medizin, Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail barton@usz.ch
(Hypertension, 2009;54:00-00.)
© 2009 American Heart Association, Inc.
Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.108.120022
menopause at an earlier age than healthy controls. Interestingly, a recent report indicates that physiological estradiol treatment in patients with premature ovarian failure results in significant reductions in blood pressure, whereas no effects on blood pressure were observed using synthetic ethinylestradiol. Consistent with the blood-pressure–lowering effect of physiological estrogens in women with ovarian failure, surgically induced menopause by bilateral oophorectomy increases blood pressure within a few weeks. In conclusion, evidence strongly support the notion that endogenous estrogens contribute to a basal vasodilatory state. Therefore, the loss of endogenous estrogens facilitates the development of hypertension in postmenopausal women and increases the cardiovascular risk associated with it.

Mechanisms of Postmenopausal Hypertension
Potential Role of Estrogen Receptors for Hypertension Development

The effects of endogenous estrogen are mediated via estrogen receptors (ERs), which include the “classic” receptors α (ERα) and β (ERβ). They are either located in the nucleus acting as ligand-activated transcription factors or are associated with the plasma membrane mediating rapid activation of...
intracellular signaling cascades. ER-dependent mechanisms regulating vascular tone include endothelium-independent vasodilation, increases in NO bioavailability, inhibition of vascular smooth muscle cell (VSMC) growth and excess proliferation after balloon injury, inhibition of the vascular renin-angiotensin-aldosterone system (RAAS) and the endothelin system, and inhibition of the sympathetic nervous system. 

Preclinical studies have investigated the contribution of ERα and ERβ for blood pressure, and the results suggest roles for both ER subtypes, depending on the animal model studied. However, these data do not reflect human physiology or human ER function, nor do they take into account differences in ER function in healthy or diseased human arteries. Thus, their value for understanding human disease may be limited. Studies investigating genetic variations in the ERα and ERβ genes in women and men suggest associations of polymorphisms of both ER subtypes with hypertension. 

It is currently unknown whether and to what extent ER-dependent or ER-independent effects, eg, antioxidant mechanisms of estrogens or inhibitory effects on the sympathetic nervous system, are involved, and how estrogen-dependent signaling pathways controlling blood pressure are altered during different stages of human life. It is, however, likely that these pathways and mechanisms are negatively affected by the presence of cardiovascular risk factors or by overt atherosclerosis.

In addition to the classic ERs, the G protein–coupled estrogen receptor GPER (formerly known as GPR30) is highly expressed in human VSMCs and arteries. We have shown recently that selective activation of GPER causes acute vasodilation in arteries from rodents and humans, reduces blood pressure in vivo even under normotensive conditions, and inhibits human VSMC proliferation, similar to what has been observed with 17β-estradiol. Future research will help to delineate the role of individual pathways contributing to the function of each known ER and will help to assess how nuclear ERα and ERβ and GPER contribute to blood pressure control and the vasoprotective effects of estrogens.
cardiovascular and renal effects, including a reduction in blood pressure.\textsuperscript{50} 2-Hydroxyestradiol and 2-methoxyestradiol stimulate the generation of the vasodilator prostacyclin, reduce endothelin-1 synthesis, and inhibit proliferation of VSMCs and glomerular mesangial cells.\textsuperscript{50} Interestingly, increased urinary 2-hydroxyestradiol concentrations in postmenopausal women are associated with lower systolic blood pressure levels.\textsuperscript{51} Although some studies have reported ER-independent growth-inhibitory actions,\textsuperscript{56,50} others suggest that the effects of 2-methoxyestradiol are mediated through ERs.\textsuperscript{52} Thus, the molecular mechanisms whereby 2-methoxyestradiol exerts its vasculoprotective effects still remain to be clarified.

**Estrogens and Effects on Blood Pressure in Humans**

**Natural Estrogen (17β-Estradiol)**

Acute arterial vasodilation in response to 17β-estradiol has been observed in several human vascular beds,\textsuperscript{13} and 17β-estradiol treatment reduces blood pressure by improving endothelium-dependent, flow-mediated vasodilation in women early after menopause.\textsuperscript{53} These data are consistent with studies showing that variations of tonic vasodilation are highly correlated with estrogen levels during the menstrual cycle.\textsuperscript{12} Accordingly, the majority of studies investigating long-term effects of 17β-estradiol on 24-hour ambulatory blood pressure demonstrated reductions in blood pressure, especially when using transdermal application of the hormone.\textsuperscript{16} Interestingly, Fisman et al\textsuperscript{54} reported that sublingual administration of 17β-estradiol lowers blood pressure in hypertensive but not in normotensive postmenopausal women. These authors also found that hypertensive individuals showed higher peak 17β-estradiol plasma concentrations than normotensive controls after administration of the hormone,\textsuperscript{54} which suggests the possibility that hypertension might affect the bioavailability of estrogens during HT.

**Animal Hormones (“Conjugated Equine Estrogens”)**

Randomized clinical trials, including the Heart and Estrogen/progestin Replacement Study (HERS) and the Women’s Health Initiative (WHI), both using conjugated equine estrogens (CEEs) obtained from the urine of pregnant horses and medroxyprogesterone acetate (MPA) for postmenopausal hormone therapy (HT), were uniformly associated with increased cardiovascular risk.\textsuperscript{55,56} However, studies have shown that, in postmenopausal women receiving HT, systolic blood pressure hardly increases over time and the nighttime fall in blood pressure (“dipping”) may be even greater than in untreated controls.\textsuperscript{16,57} In the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, blood pressure was similar in healthy women assigned to either CEE/MPA or placebo after 3 years of follow-up.\textsuperscript{58} In both the Heart and Estrogen/Progestin Replacement Study and the Women’s Health Initiative, women assigned to HT had only minimal changes in blood pressure compared with the placebo group even after several years of follow-up, although one third of women were diagnosed as hypertensive at baseline.\textsuperscript{59,60} Taken together, treatment with CEEs either alone or in combination with MPA appears to have negligible effects on arterial blood pressure in postmenopausal women.

Several aspects of the study design of Heart and Estrogen/Progestin Replacement Study and Women’s Health Initiative have been widely criticized, including that women receiving HT were in their mid-sixties and, thus, were many years after menopause; these patients also had several cardiovascular risk factors or even established coronary artery disease.\textsuperscript{33,61} Vascular aging in early postmenopausal women is associated with an increase in arterial stiffness, which facilitates the development of hypertension.\textsuperscript{62} Moreover, experimental and epidemiological evidence collectively suggest that any vascular effect of estrogens will depend on the stage of human life, the time since menopause, and the extent of pre-existing subclinical or clinically relevant atherosclerosis.\textsuperscript{33,60} Therefore, favorable effects on the vasculature, including blood pressure–lowering effects, may require that estrogen therapy be initiated early before the body adjusts to the withdrawal of endogenous estrogens.\textsuperscript{24,33,61} These important questions are currently being studied in the ongoing Kronos Early Estrogen Prevention Study (KEEPS) trial (http://www.clinicaltrials.gov No. NCT00114517) and the Early versus Late Intervention Trial with Estradiol (ELITE) Study (http://www.clinicaltrials.gov No. NCT00154180).

Treatment with CEEs cannot be considered as a “replacement” of natural human estrogens (Table). Indeed, CEEs are highly complex animal hormone mixtures containing a large number of equine estrogens with unknown selectivity and binding affinity for human ER subtypes, as well as other steroid hormones.\textsuperscript{24,33,61,63} Interestingly, no adverse vascular outcomes have been reported recently in the Women’s Hormone Intervention Secondary Prevention (WHISP) Study, which was conducted in 100 women after myocardial infarction receiving either low-dose human 17β-estradiol or placebo for 12 months.\textsuperscript{64} Moreover, the route of administration appears to be essential in determining any detrimental effects of HT, because metabolism of orally administered estrogenic compounds via hepatic first pass attenuates the vasodilatory activity and induces the RAAS, as well as procoagulatory pathways, in the liver.\textsuperscript{61,65,66} In contrast, transdermal application of estrogens avoids hepatic first pass.

<table>
<thead>
<tr>
<th>Table. Effects of Postmenopausal HT on Blood Pressure and Atherosclerotic Vascular Disease</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Potentially Beneficial</th>
<th>Potentially Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT using 17β-estradiol</td>
<td>HT using animal estrogens (CEEs)</td>
</tr>
<tr>
<td>Transdermal administration of HT</td>
<td>Oral administration of HT</td>
</tr>
<tr>
<td>Begin of HT early after menopause</td>
<td>Begin of HT late after menopause</td>
</tr>
<tr>
<td>Low dosage of HT</td>
<td>High dosage of HT</td>
</tr>
<tr>
<td>Cyclic administration of HT</td>
<td>Progestins with adverse effects (MPA)</td>
</tr>
</tbody>
</table>

Evidence suggests that the effects of hormone therapy (HT) on blood pressure depend on the type of estrogen and progestin used, dosage, the route of administration, the timing of treatment relative to menopause onset, and the overall age of the postmenopausal woman. Not shown are the additional worsening effects of the presence and/or inadequate treatment of other cardiovascular risk factors. CEEs are a mix of estrogens, progestins, and androgens extracted from the urine of pregnant horses.
and RAAS activation and lowers diastolic blood pressure when compared with oral CEE treatment. Finally, the synthetic progestin MPA not only abrogates the dilator effects of natural estrogens thereby augmenting vasoconstriction but also attenuates the estrogen-mediated inhibition of VSMC growth.

In the context of hypertension in women, we would like to point out that hypertension is a frequent adverse effect in premenopausal women taking oral contraceptives. In a prospective cohort study of 68,297 healthy premenopausal nurses, the relative risk of development of hypertension among users of oral contraceptives was 1.8 (95% CI: 1.5 to 2.3), even after adjustment for multiple other risk factors. This risk decreases with time since cessation of oral contraceptives but still remains increased even after ≥6 years (relative risk: 1.2; 95% CI: 1.0 to 1.4). Given that the contraceptive pill has been taken by women for the past half century, the question as to whether previous long-term contraceptive use plays a role in postmenopausal hypertension is of great importance; however, no data on this important medical question are currently available.

**Postmenopausal Hypertension:**

**Pathophysiology and Therapeutic Considerations**

Current estimates indicate that 130 million women in the Western world are inadequately treated for hypertension, a number that is expected to increase to 160 million in the next 20 years. Moreover, the world population is expected to increase by 50% from 6.6 billion today to 9.4 billion by the year 2050, which is mainly related to a substantial increase of aged individuals, ≈1 billion of which will be postmenopausal women (Figure, panel C). Aging remains one of the most important determinants for postmenopausal hypertension, and the growing prevalence of obesity, often in conjunction with a lack of physical activity, is likely to increase cardiovascular morbidity during the next decades.

Perimenopausal and postmenopausal women should be regularly assessed for cardiovascular risk factors by their primary care physician and their gynecologist. Lifestyle changes, eg, smoking cessation, establishing a low-fat diet rich in fruits and vegetables, increasing and maintaining regular physical activity, a normal body weight, and moderate alcohol consumption, are important in the prevention of high blood pressure and are required for the treatment of all patients, including those with prehypertension. If blood pressure control cannot be achieved by lifestyle changes alone, pharmacological therapy needs to be initiated, which is discussed in detail below. Although the loss of endogenous estrogen production after menopause contributes to the development of postmenopausal hypertension, postmenopausal HT is neither recommended for the treatment of postmenopausal hypertension nor for the primary prevention of cardiovascular disease. However, when treating younger, perimenopausal women for menopausal symptoms, the benefits should always be weighed against the potential risks of HT, and the type of HT should be carefully chosen (Table).

Drospirenone, a novel progestin with mineralocorticoid antagonist activity, has been shown to lower blood pressure in hypertensive postmenopausal women when combined with 17β-estradiol. It is possible that this new therapy offers advantages for patients with postmenopausal hypertension who require progestin therapy for uterine protection during HT for menopausal symptoms. Finally, selective ER modulators, eg, raloxifene, which are agonists for the novel vasodilating estrogen receptor GPER could possibly be used in the treatment of postmenopausal hypertension.

The current US guidelines for treatment of arterial hypertension (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommend the use of a thiazide-type diuretic as a first-line agent in most patients if target blood pressure cannot be achieved with lifestyle changes alone. Indeed, the high prevalence of salt-sensitive hypertension in postmenopausal women strongly supports dietary salt restriction and the use of diuretics as the preferred initial agent. Both reducing dietary sodium and using a thiazide-type diuretic improve blood pressure control and also reduce subsequent cardiovascular complications of hypertension. Interestingly, dietary salt restriction shows a more pronounced antihypertensive effect in elderly women than in men, again arguing in favor of a pathogenic role of cessation of endogenous estrogen production in the pathogenesis of salt sensitivity.

When target blood pressure cannot be achieved by the use of a single agent, the addition of a second drug from a different class should be initiated. This may be particularly important in postmenopausal women with the metabolic syndrome, who often present with a more severe cardiovascular risk profile and show a less favorable response to antihypertensive therapy than their lean counterparts because of resistant hypertension. The use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been proposed in this context. These drugs appear to be useful to antagonize the activation of the RAAS observed after menopause. Interestingly, a small study among 51 postmenopausal hypertensive women demonstrated recently that the blood pressure–lowering effect of the angiotensin receptor blocker irbesartan is augmented by co-administration with 17β-estradiol, suggesting potentiating effects of 2 different antihypertensive mechanisms and underscoring a need for further research in this area. New antihypertensive paradigms, eg, GPER agonism, which has been shown to work experimentally, could possibly evolve.

**Perspectives**

The ultimate goal of primary and secondary prevention of hypertension in postmenopausal women is the reduction of morbidity and mortality of adverse clinical events, eg, stroke, myocardial infarction, and hypertensive nephropathy. Currently, control of blood pressure in postmenopausal women often remains suboptimal. We need to continue our efforts in screening and identifying patients, improving patient and physician awareness, and optimizing clinical care and public health measures. This includes distributing information to senior citizens and educational institutions. Finally, prevention of hypertension in women should not only be focused on adult women but must start early in life, as indicated by the
rising number of school girls diagnosed with hypertension attributed to obesity. 87–89

Sources of Funding
This work was supported by grants from the Swiss National Science Foundation (3200-108258/1 and K-33KO122504/1) and by the University of Zurich.

Disclosures
None.

References


86. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the GPR30 agonist G-1 decreases blood pressure in ovariectomized mREN2 Lewis rats. Endocrinology. In press.


76. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the GPR30 agonist G-1 decreases blood pressure in ovariectomized mREN2 Lewis rats. Endocrinology. In press.


Postmenopausal Hypertension. Mechanisms and Therapy
Matthias Barton and Matthias R. Meyer

Hypertension. published online May 26, 2009;
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2009/05/26/HYPERTENSIONAHA.108.120022.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/